AI Engines For more Details: Perplexity Kagi Labs You
Immune Modulation: Ganoderma lucidum mycelium contains bioactive compounds, including polysaccharides, triterpenes, and proteins, which may help modulate the immune system. These compounds are believed to enhance the activity of immune cells such as macrophages, natural killer cells, and T lymphocytes, which play a crucial role in defending the body against infections and diseases.
Antioxidant Activity: Ganoderma lucidum mycelium is rich in antioxidants, including polysaccharides and triterpenes, which help neutralize harmful free radicals and reduce oxidative stress in the body. By scavenging free radicals, Ganoderma lucidum mycelium may help protect cells from damage, reduce inflammation, and lower the risk of chronic diseases such as cardiovascular disease and cancer.
Anti-inflammatory Properties: Some studies suggest that Ganoderma lucidum mycelium possesses anti-inflammatory properties, which may help alleviate inflammation in the body. Chronic inflammation is associated with various health conditions, including arthritis, diabetes, and cardiovascular disease. By reducing inflammation, Ganoderma lucidum mycelium may help mitigate the symptoms of inflammatory conditions and promote overall health.
Antimicrobial Effects: Ganoderma lucidum mycelium contains compounds with antimicrobial properties, which may help inhibit the growth of bacteria, viruses, and fungi. These antimicrobial effects may contribute to the traditional use of Ganoderma lucidum in preventing and treating infections, including respiratory infections, urinary tract infections, and skin infections.
Stress Reduction: Some research suggests that Ganoderma lucidum mycelium may have adaptogenic properties, meaning it helps the body adapt to stress and maintain balance. By modulating the body's stress response, Ganoderma lucidum mycelium may help reduce the negative effects of stress on overall health and well-being.
Liver Protection: Ganoderma lucidum mycelium has been studied for its potential hepatoprotective effects, meaning it may help protect the liver from damage caused by toxins, alcohol, and other harmful substances. By promoting liver health and supporting detoxification processes, Ganoderma lucidum mycelium may help improve overall metabolic function and reduce the risk of liver diseases.
Anti-cancer Potential: Some preliminary studies suggest that Ganoderma lucidum mycelium may possess anti-cancer properties, including the ability to inhibit the growth of cancer cells and promote apoptosis (programmed cell death) in tumor cells. While more research is needed to fully understand its effects, Ganoderma lucidum mycelium shows promise as a potential adjunct therapy for cancer prevention and treatment.
Rank | Probiotic | Impact |
---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.7 | 1.8 | -1.57 |
ADHD | 0.2 | 1.2 | -5 |
Allergic Rhinitis (Hay Fever) | 0.2 | -0.2 | |
Allergies | 0.5 | 1.7 | -2.4 |
Allergy to milk products | 1.9 | -1.9 | |
Alopecia (Hair Loss) | 0.5 | 0.5 | |
Alzheimer's disease | 1.4 | 2.3 | -0.64 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | -1.7 | |
Ankylosing spondylitis | 0.5 | 1.2 | -1.4 |
Anorexia Nervosa | 0.8 | 0.7 | 0.14 |
Asthma | 0.5 | -0.5 | |
Atherosclerosis | 1.2 | 1.2 | |
Autism | 1 | 1.9 | -0.9 |
Bipolar Disorder | 0.5 | 1.7 | -2.4 |
Brain Trauma | 0.4 | 0.2 | 1 |
Breast Cancer | 0.4 | 0.4 | |
Celiac Disease | 1.2 | 0.5 | 1.4 |
Chronic Fatigue Syndrome | 2.1 | -2.1 | |
Chronic Kidney Disease | 1.1 | -1.1 | |
Chronic Urticaria (Hives) | 1.4 | 1.4 | |
Coagulation / Micro clot triggering bacteria | 0.5 | 0.2 | 1.5 |
Colorectal Cancer | 0.5 | 1.2 | -1.4 |
COVID-19 | 1.8 | 2.3 | -0.28 |
Crohn's Disease | 1.3 | 1.7 | -0.31 |
deep vein thrombosis | 0.2 | -0.2 | |
Depression | 2.1 | 1.4 | 0.5 |
Dermatomyositis | 1.7 | -1.7 | |
Eczema | 1.4 | -1.4 | |
Endometriosis | 0.5 | 0.3 | 0.67 |
Eosinophilic Esophagitis | 2.4 | -2.4 | |
Epilepsy | 1.3 | 0.5 | 1.6 |
Fibromyalgia | 0.2 | 0.2 | |
Functional constipation / chronic idiopathic constipation | 0.5 | 1.7 | -2.4 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.6 | -0.2 |
Generalized anxiety disorder | 0.2 | 0.2 | |
giant cell arteritis | 0.2 | -0.2 | |
Gout | 1.3 | 1.4 | -0.08 |
Graves' disease | 0.7 | 2.6 | -2.71 |
Halitosis | 0.2 | 0.2 | |
Heart Failure | 0.5 | 0.5 | |
Hidradenitis Suppurativa | 0.5 | -0.5 | |
hypercholesterolemia (High Cholesterol) | 0.2 | 0.2 | |
Hyperlipidemia (High Blood Fats) | 1.2 | 0.5 | 1.4 |
hypertension (High Blood Pressure | 1.2 | 1.2 | |
Inflammatory Bowel Disease | 1.2 | 0.9 | 0.33 |
Insomnia | 0.5 | -0.5 | |
Intracranial aneurysms | 0.2 | 0.2 | |
Irritable Bowel Syndrome | 0.7 | 0.5 | 0.4 |
Juvenile idiopathic arthritis | 1.1 | -1.1 | |
Long COVID | 2.4 | 2.9 | -0.21 |
Lung Cancer | 0.7 | -0.7 | |
Metabolic Syndrome | 1.9 | 1.6 | 0.19 |
Mood Disorders | 2.6 | 2.6 | 0 |
Multiple Sclerosis | 1.7 | 0.6 | 1.83 |
Neuropathy (all types) | 1.9 | 1.2 | 0.58 |
neuropsychiatric disorders (PANDAS, PANS) | 1.1 | -1.1 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.1 | 1.1 | |
Obesity | 1.2 | 1.2 | 0 |
Osteoarthritis | 0.5 | -0.5 | |
Osteoporosis | 0.6 | 1.7 | -1.83 |
Parkinson's Disease | 0.2 | 1.4 | -6 |
Polycystic ovary syndrome | 0.2 | 0.2 | |
Premenstrual dysphoric disorder | 1.2 | 1.2 | |
Psoriasis | 2.9 | 2.9 | |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.5 | 0.6 | -0.2 |
Rosacea | 1.7 | -1.7 | |
Schizophrenia | 0.7 | 1.9 | -1.71 |
Sjögren syndrome | 0.5 | 0.5 | |
Sleep Apnea | 0.5 | 0.5 | |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | -0.5 | |
Stress / posttraumatic stress disorder | 0.5 | -0.5 | |
Systemic Lupus Erythematosus | 1.9 | 1.2 | 0.58 |
Type 1 Diabetes | 1.1 | 0.6 | 0.83 |
Type 2 Diabetes | 1.9 | 1.6 | 0.19 |
Ulcerative colitis | 2.6 | 2.3 | 0.13 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.